CP
ALNY icon

Corbenic Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Corbenic Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5
Closed -$1K – 212
2022
Q1 		$1K Hold
5
– – ﹤0.01% 217
2021
Q4 		$1K Hold
5
– – ﹤0.01% 260
2021
Q3 		$1K Hold
5
– – ﹤0.01% 261
2021
Q2 		$1K Hold
5
– – ﹤0.01% 237
2021
Q1 		$1K Hold
5
– – ﹤0.01% 227
2020
Q4 		$1K Hold
5
– – ﹤0.01% 181
2020
Q3 		$1K Hold
5
– – ﹤0.01% 153
2020
Q2 		$1K Sell
5
-6
-55% -$809 ﹤0.01% 145
2020
Q1 		$1K Hold
11
– – ﹤0.01% 162
2019
Q4 		$1K Buy
+11
New +$1.1K ﹤0.01% 167

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Corbenic Partners's ALNY Position: Q2 2022 in Review

Corbenic Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2022, closing a stake of 5 shares — an estimated $1K sold.

Corbenic Partners first reported a position in ALNY in Q4 2019 and held it in 10 quarters. The position peaked at $1K in Q1 2022. 421 funds tracked by Wall St. Rank hold ALNY as of Q2 2022.

  • Corbenic Partners reported no remaining Alnylam Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Corbenic Partners sold 5 Alnylam Pharmaceuticals shares in Q2 2022, an estimated $1K.
  • Corbenic Partners first reported a position in Alnylam Pharmaceuticals in Q4 2019 and held it in 10 quarters.
  • Corbenic Partners's Alnylam Pharmaceuticals position peaked at $1K in Q1 2022.
  • 421 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2022.

Based on Corbenic Partners's 13F filing for Q2 2022, filed 25 Jul 2022.